News

Non-invasive PGT-A tracked live birth in a blinded study, yet a third of ‘aneuploid’ embryos still became babies

A third of aneuploid embryos became babies, IVF News Update

· IVF Automation News

Summary

A blinded study from Instituto Bernabeu in Alicante, Spain, published online in Fertility and Sterility on 10 November 2026, ran non-invasive PGT-A (niPGT-A) on the spent culture medium of 154 single fresh blastocyst transfers in donor-egg cycles. Embryos called euploid led to a live birth more often (56.0%) than those called aneuploid (36.7%). But 14 of 43 embryos with whole-chromosome aneuploid calls still resulted in a live birth, and adding the test did not significantly improve prediction beyond standard morphology grading.

Non-invasive PGT-A promises chromosome screening without touching the embryo: instead of taking a biopsy, the lab sequences DNA the embryo has shed into its culture drop. This new study shows where that promise stands. The test’s calls lined up with live birth, but not closely enough to decide which embryos to transfer or set aside.

How was the study designed?

The team enrolled women aged 30 to 50 having their first single fresh blastocyst transfer in their first donor-oocyte cycle. Embryologists chose embryos on morphology alone. After transfer, the spent medium was collected and sequenced (VeriSeq, Illumina). The results were blinded and played no part in clinical decisions.

This “non-selection” design is the study’s strength. Because embryos later called aneuploid were transferred too, the researchers could see what actually happened to them, something a study that discards “abnormal” embryos can never show. The main outcome was live birth; secondary outcomes included biochemical pregnancy, clinical pregnancy and miscarriage.

What did it find?

The authors conclude that the test was associated with live birth, but that its diagnostic performance, added prognostic value and clinical usefulness still need to be established.

Why does this matter if niPGT-A is not used clinically?

ESHRE’s 2023 good practice recommendations on add-ons already state that “non-invasive PGT is currently not recommended for routine clinical use” and that its diagnostic accuracy “has not reached a sufficient level to be considered for selection of embryos.” This study adds live-birth data from transfers made without the test influencing the choice, which is the kind of evidence that guidance was waiting for. The answer, for now, supports ESHRE’s caution.

It also arrives a day after a Nature Cell Biology study on RNA released into spent culture medium, and alongside a November RBMO paper that used mass spectrometry and machine learning on 120 medium samples, reporting 91% accuracy against biopsy-based PGT-A. Matching a biopsy result is not the same as predicting a baby, and only the Bernabeu study measured live birth.

What does it mean for embryologists and lab managers?

Labs that already log culture conditions and sample handling consistently, for example with our free lab QC tools, are better placed to join validation studies.

What is the India and global angle?

In India, Section 25 of the Assisted Reproductive Technology (Regulation) Act, 2021 frames pre-implantation genetic testing around screening embryos for known, pre-existing, heritable or genetic diseases. How any form of aneuploidy screening fits that wording is a question for clinics’ legal advisers and the regulators, not a lab decision. Abroad, public payers are already questioning biopsy-based PGT-A; our report on PGT-A cost-effectiveness in Israel and Ontario covers that debate. Molecular or AI embryo-ranking tools face the same evidence bar, as our guide to AI embryo assessment under FDA and CDSCO explains.

What is the commercial outlook?

The study had no external funding and the authors report no disclosures. For companies developing niPGT-A kits and services, the bar is now outcome data from non-selection studies, not concordance with biopsy alone. On this evidence, the near-term role of medium-based testing looks like research and possible prognostic support rather than a basis for discarding embryos. Larger studies, including in patients using their own eggs, are the next step.

This article reports a research study. It is not medical advice.

Sources

  1. Lledo B, Morales R, Ortiz JA, … Castillo JC, Bernabeu A, “Association between non-invasive PGT-A (niPGT-A) and live birth using spent embryo culture medium in donor oocyte cycles: a prospective non-selection cohort study”, Fertility and Sterility, published online 10 Nov 2026 (peer-reviewed, article in press). https://www.fertstert.org/article/S0015-0282(26)01883-2/abstract
  2. Same study, DOI record: 10.1016/j.fertnstert.2026.11.006. https://doi.org/10.1016/j.fertnstert.2026.11.006
  3. De-identified niPGT-A results dataset (CSV), Zenodo, linked from the paper’s data-sharing statement. https://doi.org/10.5281/zenodo.21892903
  4. ESHRE Add-ons Working Group, “Good practice recommendations on add-ons in reproductive medicine”, Human Reproduction, 2023 (professional society guidance). https://pmc.ncbi.nlm.nih.gov/articles/PMC10628516/
  5. Walsh R, Mancera L, Ahmady A, Arrach N, “Non-invasive prediction of embryo ploidy status using metabolomic profiling and machine learning”, Reproductive BioMedicine Online, Nov 2026 (peer-reviewed, retrospective). https://www.sciencedirect.com/science/article/abs/pii/S1472648326004335
  6. The Assisted Reproductive Technology (Regulation) Act, 2021, section 25 (statute text). https://legislations.in/central/2021/the-assisted-reproductive-technology-regulation-act-2021/section-25

Tags: non-invasive PGT-A, niPGT-A live birth, spent culture medium, embryo culture medium DNA, donor oocyte IVF, Fertility and Sterility study, embryo selection, Instituto Bernabeu

Get IVF Automation Weekly

The week's verified IVF industry news in your inbox.